Introduction
============

Medical development has increased the average human lifespan ([@B58]). Cognitive functions such as memory often decline as humans age ([@B57]), and aging is the major risk factor for Alzheimer's disease ([@B14]). Human brain becomes atrophied with the aging ([@B15]), although brain atrophy remains mild in some elderly people called "superager" or "successful aging" whose cognitive functions remain intact with age ([@B9]; [@B22]; [@B54]).

Neuronal systems responsible for brain function are known to decline with age ([@B39]). In the human brain, neuroimaging studies revealed that endogenous dopamine, and dopamine transporter, D~1~ and D~2~ receptors and aromatic [L]{.smallcaps}-amino acid decarboxylase decrease with age ([@B53]; [@B46]; [@B23]), while monoamine oxidase B increases with age ([@B46]). Such age-related decrease has also been reported in the cholinergic, glutamatergic and γ-aminobutyric acid (GABA)ergic systems ([@B51]; [@B47]; [@B49]).

In the adenosinergic system, animal studies reported that the age-related changes differ in the subtypes: adenosine A~1~ (A~1~R) and A~2A~ receptors (A~2A~R) ([@B6], [@B7]; [@B32]; [@B45]; [@B33]). We developed ligands for positron emission tomography (PET) to map the adenosine receptors, and successfully visualized the A~1~Rs using 8-dicyclopropylmethyl-1-^11^C-methyl-3-propylxanthine (^11^C-MPDX, **Figure [1](#F1){ref-type="fig"}**) ([@B19]) and the A~2A~Rs using \[7-methyl-^11^C\]-(*E*)-8-(3,4,5-trimethoxystyryl)-1,3,7-trimethylxanthine (^11^C-TMSX) ([@B24],[@B25], [@B26]). Using ^11^C-MPDX and ^11^C-TMSX PET, we previously reported that the density of A~1~Rs decreased with age in the human striatum, although we could not observe an age-related change in A~2A~Rs ([@B37]). In order to compare A~1~R and A~2A~R, we did not study the density of A~1~Rs other than striatum in the past paper ([@B37]). Because A~2A~Rs are enriched in the striatum ([@B17]; [@B36]), while A~1~Rs are widely distributed throughout the entire human brain ([@B19]). Another human PET study reported that the binding ability of ^18^F-8-cyclopentyl-3-(3-fluoropropyl)-1-propylxanthine (^18^F-CPFPX), an A~1~R ligand, was negatively correlated with age in the cerebral cortices and thalamus in addition to the striatum ([@B34]). The A~1~Rs in the cerebral cortex are thought to help regulate the GABAergic and glutamatergic systems ([@B1]; [@B8]; [@B13]), while A~1~Rs in the striatum are mainly responsible for the regulation of the D~1~ receptor in medium spiny neurons ([@B12]; [@B59]). We hypothesized that the A~1~Rs may decrease with age in the thalamus and cerebral cortices. The aim of this study was to investigate the age-related change in the density of A~1~Rs in the thalamus and cerebral cortices of healthy participants using ^11^C-MPDX PET.

![Chemical structures of ^11^C-MPDX.](fphar-08-00903-g001){#F1}

Materials and Methods {#s1}
=====================

Participants
------------

We recruited eight young healthy (mean age ± standard deviation \[SD\], 22.0 ± 1.7 years, age range, 20--25 years) and nine elderly male volunteers (65.7 ± 8.0 years, age range, 51--77 years). The participants were all Japanese and right-handed. None of the participants had a history of neurological diseases or any abnormalities upon physical or neurological examinations. Additionally, none took any medications known to affect the brain function or had a history of alcoholism. They had no medical history of bronchial asthma, and did not regularly use theophylline, a nonselective A~1~R and A~2A~R antagonist.

This study was approved by the Ethics Committee of Tokyo Metropolitan Institute of Gerontology. Written, informed consent was obtained from all participants in this study.

Magnetic Resonance Imaging (MRI)
--------------------------------

MRI was performed in the Tokyo Metropolitan Geriatric Hospital with three-dimensional spoiled gradient-recalled echo (SPGR) imaging and a SIGNA 1.5 Tesla machine (General Electric, Waukesha, WI, United States). The MRI images validated that the participants had no neurological diseases, such as stroke or brain tumors, and were used as a reference for placing the regions of interest (ROIs) on the PET images.

PET Measurements
----------------

Positron emission tomography was performed in the Positron Medical Center, Tokyo Metropolitan Institute of Gerontology with a SET-2400W PET scanner (Shimadzu, Kyoto, Japan). The scanner had an axial field-of-view of 20 cm, acquired 63 slices at a center-to-center interval of 3.125 mm, and had a spatial resolution of 4.4 mm full width at half maximum (FWHM) and a z-axis resolution of 6.5 mm FWHM ([@B18]). All participants were asked to abstain from caffeinated beverages, such as tea and coffee, and foods containing chocolate, for 12 h prior to undergoing the ^11^C-MPDX PET, because caffeine is a non-selective adenosine receptor antagonist ([@B52]). ^11^C-MPDX was prepared as described previously ([@B19]). To obtain an attenuation map to correct for photon attenuation, an 8-min transmission scan with a rotating ^68^Ga/^68^Ge line source was recorded before the radiotracer injection. Starting at the time of injection, a dynamic series of decay-corrected PET scans was performed for 60 min in a two-dimensional scanning mode. The injected dose of ^11^C-MPDX was 639 ± 77 MBq (16.0 ± 11.6 nmol). Specific activity at the time of injection ranged from 14.6 to 129.5 TBq/mmol (59.5 ± 36.8 TBq/mmol). The total number of frames was 27 and the frame arrangements were 6 × 10 s, 3 × 30 s, 5 × 1 min, 5 × 2.5 min, and 8 × 5 min.

Image Processing
----------------

Image analyses were carried out with the medical image processing software Dr. View/Linux R2.5 (AJS, Tokyo, Japan) implemented in CentOS 5.4 (The CentOS Project^[1](#fn01){ref-type="fn"}^) and Parallels Desktop 5.0.9344 (Parallels Holdings, Renton, WA, United States).

We generated early images, which were considered similar to images for cerebral blood flow, by summing frames from 0 to 10 min ([@B38]). The MRI image was three-dimensionally registered to the early image of each participant. The early images and the registered MRI images were used as references for placing each ROI on the PET images from the dynamic scans. Circular ROIs with 10 mm in diameter were placed bilaterally on the PET images over the thalamus, frontal, temporal, occipital, and parietal cortex. We also placed the circular ROI over the cerebellar hemisphere as a reference region for kinetic analysis. Averaged tissue time activity curves (tTACs) were derived from the dynamic data and ROI, and data were used to calculate the standardized uptake value.

Kinetic analyses of the tTACs were performed using programs implemented on MATLAB version 7.04 (The Mathworks, Natick, MA, United States) and a General Kinetic Modeling Tool in PMOD 3.0 (PMOD Technologies, Zurich, Switzerland). The values for the binding potential (*BP*~ND~) of ^11^C-MPDX ([@B27]) in the regions were calculated using an averaged tTAC and a graphical analysis with the cerebellum as the reference region ([@B31]), where the *k*~2~ of the reference region was 0.23/min that was the averaged *k*~2~ as presented in the **Table 1** of a past paper ([@B27]) and the starting time for the analysis was 10 min after the administration. We confirmed that the *BP*~ND~ of ^11^C-MPDX was suitable for evaluating the distribution of A~1~Rs ([@B27]).

Statistical Analysis
--------------------

Statistical computations were performed using the software package JMP Pro version 13.2.0 (SAS Institute, Cary, NC, United States). If the variance had a significant difference between young and elderly groups with Bartlett's test, Welch's t-test were used to compare the *BP*~ND~ of ^11^C-MPDX. If not, unpaired *t*-tests were used instead. We also used the regression analysis to compare the age with the *BP*~ND~ of participants. The level of significance was set at *p* \< 0.05.

Results
=======

**Figure [2](#F2){ref-type="fig"}** shows representative ^11^C-MPDX PET images. *BP*~ND~ of ^11^C-MPDX was significantly smaller in elderly participants than young participants in the thalamus (young *vs.* elderly; 0.43 ± 0.07 *vs.* 0.33 ± 0.06, *p* \< 0.01; unpaired *t*-test), frontal (0.19 ± 0.04*vs.* 0.12 ± 0.04, *p* \< 0.001; unpaired *t*-test), temporal (0.29 ± 0.05 *vs.* 0.21 ± 0.06, *p* \< 0.05; unpaired *t*-test), occipital (0.31 ± 0.05 *vs.* 0.23 ± 0.06, *p* \< 0.05; unpaired *t*-test), and parietal cortices (0.27 ± 0.05 *vs.* 0.20 ± 0.06, *p* \< 0.05; unpaired *t*-test, **Figure [3](#F3){ref-type="fig"}**).

![^11^C-MPDX PET images for a 22-year-old male subject **(A)** and a 77-year-old male subject **(B)**. The pixel values for the PET images of ^11^C-MPDX are visualized as the distribution volume ratio (*DVR*), because the brain anatomy is unclear in the *BP*~ND~ images of ^11^C-MPDX. Note that we use the values for the binding potential (*BP*~ND~) in the kinetic analysis for ^11^C-MPDX PET in **Figures [3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}**.](fphar-08-00903-g002){#F2}

![*BP*~ND~ of ^11^C-MPDX in the young and elderly participants. *BP*~ND~ of ^11^C-MPDX was significantly smaller in elderly participants than young participants in the thalamus, frontal, temporal, occipital, and parietal cortex. THL, thalamus; FRC, frontal cortex; TMC, temporal cortex; OCC, occipital cortex; PRC, parietal cortex. ^∗^*p* \< 0.05, ^†^*p* \< 0.01, ^‡^*p* \< 0.001, unpaired *t*-test.](fphar-08-00903-g003){#F3}

Regression analyses also showed that the *BP*~ND~ of ^11^C-MPDX was negatively correlated with age in the thalamus (*R*^2^ = 0.458; *p* \< 0.005, **Figure [4A](#F4){ref-type="fig"}**), and frontal (*R*^2^ = 0.500; *p* \< 0.005, **Figure [4B](#F4){ref-type="fig"}**), temporal (*R*^2^ = 0.402; *p* \< 0.01, **Figure [4C](#F4){ref-type="fig"}**), occipital (*R*^2^ = 0.338; *p* \< 0.05, **Figure [4D](#F4){ref-type="fig"}**), and parietal cortices (*R*^2^ = 0.349; *p* \< 0.05, **Figure [4E](#F4){ref-type="fig"}**).

![Scattergrams of age *vs. BP*~ND~ of ^11^C-MPDX. *BP*~ND~ of ^11^C-MPDX was negatively correlated with age in the thalamus **(A)**, and frontal **(B)**, temporal **(C)**, occipital **(D)**, and parietal cortices **(E)**.](fphar-08-00903-g004){#F4}

Discussion
==========

In the human thalamus and cerebral cortices, we observed an age-related decrease of the *BP*~ND~ of ^11^C-MPDX, which is in line with previous findings in the striatum ([@B37]). Two reasons are considered to have reduced the *BP*~ND~ of ^11^C-MPDX, namely (1) reduced binding site and (2) increased endogenous adenosine. If the concentration of extracellular adenosine is increased, the estimated apparent *BP*~ND~ using ^11^C-MPDX is decreased by competition at the A~1~R between endogenous adenosine and ^11^C-MPDX. Extracellular adenosine levels in the striatum were not affected by age ([@B4]), although no data are available on adenosine in the cerebral cortex. In addition, the affinity of ^11^C-MPDX is higher than that of adenosine ([@B42]; [@B40]; [@B35]). These findings weaken the counter-hypothesis that the age-related decrease in the *BP*~ND~ of ^11^C-MPDX involved an increase in adenosine. Therefore, the results involved an age-related decrease in A~1~Rs in the human brain.

Some studies have revealed differences in age-related changes between A~1~Rs and A~2A~Rs ([@B4]). The age-related changes vary in different brain regions. [@B6] studied age-related changes in rats, using \[^3^H\]2-\[4-(2-p-carboxyethyl)phenylamino\]-5′-*N*-ethylcarboxamidoadenosine (^3^H-CGS 21680) for A~1~Rs and \[^3^H\]-1,3-dipropyl-8-cyclopentylxanthine (^3^H-DPCPX) for A~2A~Rs. In their study, A~1~Rs were decreased in the cerebral cortex and hippocampus, but A~2A~Rs were increased only in the cerebral cortex of aged rats. No significant changes were observed in A~1~R of the striatum and in A~2A~R of both the hippocampus and the striatum. An autoradiography study using \[^3^H\]N6-cyclohexyladenosine demonstrated that there was an age-dependent reduction in A~1~Rs in most of the brain areas of rats, but that the degree of the reduction varied among regions ([@B33]). Efficiency of A~2A~Rs to modulate synaptic transmission in the hippocampus was decreased in aged rats ([@B50]), although the efficiency of A~2A~Rs was increased by aging ([@B32]; [@B45]). It seems that there are age-related changes in the balance between inhibitory A~1~R- and excitatory A~2A~R-mediated actions.

A limitation the lack of data on participants' daily sleep state. A~1~R and A~2A~R play an important role in regulating sleep ([@B2]; [@B48]; [@B56]; [@B11]; [@B44]). Some studies showed that sleep deprivation increased A~1~R ([@B2]; [@B11]). Another study suggested that endogenous adenosine suppressed the histaminergic system via A~1~R to promote non-rapid eye movement sleep ([@B44]). Many elderly people are suffering from insomnia ([@B10]; [@B43]; [@B5]). The age-related changes to A~1~R may be associated with insomnia in elderly people.

Another limitation of this study was the lack of data on participants' daily caffeine intake. In this study, we restricted caffeine consumption in the 12 h prior to performing PET scans, because caffeine is a non-selective adenosine receptor antagonist. Many elderly Japanese people habitually drink green tea after meals ([@B29]), although the overall caffeine consumption is attributed more to coffee than to tea in Japan ([@B16]). Animal studies reported that chronic administration of caffeine increases the density of adenosine receptors ([@B21]; [@B41]; [@B30]), although human data are sparse. Another limitation the lack of data on participants' daily sleep state. Adenosine is involved in circadian rhythm and sleep ([@B3]), and adenosine inhibits the arousal system via A~1~R and induces sleep ([@B44]). Elderly people often have sleep disorders. Further studies are needed to reveal the relationship between chronic caffeine consumption and A~1~R density.

Our study was only comprised of males. A post-mortem study reported adenosine level in the cerebral cortex was higher in male than in female ([@B28]). However, some papers showed that there was no significant gender effect on A~1~Rs in the human brain ([@B55]; [@B20]; [@B34]).
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